首页 > 市场调查报告书 > 材料

市场调查报告书

商品编码

1524322

类器官和球体市场 - 按类型（类器官、球体）、应用（发育生物学、个人化医疗）、最终用途（製药和生物技术公司、学术和研究机构） - 全球预测（2024 - 2032）

Organoids and Spheroids Market - By Type (Organoids, Spheroids), Application (Developmental Biology, Personalized Medicine), End-use (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes) - Global Forecast (2024 - 2032)

出版日期: 2024年04月22日 | 出版商:

Global Market Insights Inc. | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

简介目录

由于生物技术（特别是 3D 细胞培养和生物工程）的进步，加上个人化医疗需求的不断增长，2024 年至 2032 年全球类器官和球体市场规模的复合年增长率将达到 19.1%。技术的涌入使得精确的疾病建模、药物测试和客製化治疗方法成为可能，从而提高治疗效果和患者的治疗效果。

随着药物研究和再生医学领域的应用不断增加，类器官和球体提供了创新的解决方案来满足疾病的复杂性，推动全球研究和临床环境的成长。例如，2024 年 1 月，HUB Organoids HUB 透过利用 IBD 患者来源的类器官单层 PDO 单层推出了 IntegriGut Screen，以提供有关上皮屏障功能的重要人类资料。

类器官和球体产业分为类型、应用、最终用途和地区。

从最终用途来看，由于在推进生物技术研究方面发挥关键作用，学术和研究机构部门到 2032 年将经历强劲成长。这些机构正在推动 3D 细胞培养技术的创新，以增强疾病建模和药物测试能力。凭藉雄厚的资金以及与製药公司的合作，学术和研究机构正在为治疗开发和个人化医疗做出重大贡献。

在应用方面，在客製化治疗方法的推动下，个人化医疗领域的类器官和球体市场将在 2024 年至 2032 年间实现大幅复合年增长率。类器官和球体提供精确的疾病建模和药物测试，这对于开发针对患者的特定疗法至关重要。随着生物技术的进步和药物研究应用的增加，个人化医疗也利用 3D 细胞培养模型来优化治疗结果，从而推动细分市场的显着成长。

在生物技术和製药领域投资增加的刺激下，亚太类器官和球体市场将在 2024 年至 2032 年间呈现可观的复合年增长率。强大的研究基础设施和不断增长的医疗保健支出正在促进先进 3D 细胞培养技术的采用。随着药物发现和个人化医疗领域不断涌现，亚太地区将成为产业成长的关键贡献者。

产业生态系统分析
产业影响力
- 成长动力
  - 细胞培养技术的进步
  - 个人化医疗需求增加
  - 慢性病盛行率上升
  - 3D球体的技术进步
- 产业陷阱与挑战
  - 缺乏稳健的疾病模型
  - 开发和维护成本高
成长潜力分析
技术景观
监管环境
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按类型，2018 - 2032

主要趋势
类器官
- 按类型
  - 神经类器官
  - 肝类器官
  - 肠类器官
  - 其他类器官类型
- 依方法
  - 类器官培养的通用液体培养法
  - 隐窝类器官培养技术
  - 气液界面（ALI）法
  - 其他类器官方法
- 按来源
  - 原代组织
  - 干细胞
球体
- 按类型
  - 多细胞肿瘤球体
  - 神经球
  - 微球体
  - 肝球
- 依方法
  - 微图案板
  - 低细胞附着板
  - 悬滴法
  - 其他球体方法
- 按来源
  - 细胞系
  - iPSC 衍生细胞

第 6 章：市场估计与预测：按应用划分，2018 年 - 2032 年

主要趋势
发育生物学
个人化医疗
再生医学
疾病病理研究
药物毒性及药效测试

第 7 章：市场估计与预测：按最终用途，2018 - 2032 年

主要趋势
製药和生物技术公司
学术及研究机构
医院和诊断中心

第 8 章：市场估计与预测：按地区划分，2018 年 - 2032 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

STEMCELL Technologies
Corning Incorporated
Merck KGaA
Greiner Bi-One
InSphero Inc.
Promega Corporation
Thermo Fisher Scientific Inc.
Lonza Group Ltd.
Prellis Biologics
AMSBIO LLC

简介目录

Product Code: 9142

Global Organoids and Spheroids Market size will record 19.1% CAGR from 2024 to 2032 due to advancements in biotechnology, particularly in 3D cell culture and bioengineering, coupled with the rising demand for personalized medicine. The influx of technologies is enabling precise disease modeling, drug testing, and tailored treatment approaches for enhancing therapeutic efficacy and patient outcomes.

With increasing applications across pharmaceutical research and regenerative medicine, organoids and spheroids offer innovative solutions to cater to the complexities of diseases, driving growth in both research and clinical settings globally. For instance, in January 2024, HUB Organoids HUB introduced the IntegriGut Screen by utilizing IBD patient-derived organoid monolayers PDO monolayers to provide crucial human data on epithelial barrier function.

The organoids and spheroids industry is classified into type, application, end-use, and region.

By end-use, the academic and research institutes segment will experience robust growth through 2032, attributed to the pivotal role in advancing biotechnological research. These institutions are driving innovations in 3D cell culture technologies for enhancing disease modeling and drug testing capabilities. With robust funding and collaborations with pharmaceutical companies, academic and research institutes are contributing significantly to therapeutic development and personalized medicine.

In terms of application, the organoids and spheroids market from the personalized medicine segment will witness substantial CAGR between 2024 and 2032, propelled by the tailored approach to treatment. Organoids and spheroids offer precise disease modeling and drug testing, which is crucial for developing patient-specific therapies. With advancements in biotechnology and increased adoption in pharmaceutical research, personalized medicine is also leveraging 3D cell culture models to optimize treatment outcomes, driving significant segment growth.

Asia Pacific organoids and spheroids market will demonstrate a decent CAGR between 2024 and 2032, spurred by increasing investments in biotechnology and pharmaceutical sectors. The robust research infrastructure and growing healthcare expenditure is fostering the adoption of advanced 3D cell culture technologies. With rising initiatives in drug discovery and personalized medicine, Asia Pacific will stand out as a key contributor to the industry growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Advancement in cell culture technologies
  - 3.2.1.2 Increase in demand for personalized medicine
  - 3.2.1.3 Rise in prevalence of chronic disease
  - 3.2.1.4. Technological advancement in 3 D spheroid
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Lack of robust disease models
  - 3.2.2.2 High cost of development and maintenance
3.3 Growth potential analysis
3.4 Technology landscape
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Organoids
- 5.2.1 By Type
  - 5.2.1.1 Neural organoids
  - 5.2.1.2 Hepatic organoids
  - 5.2.1.3 Intestinal organoids
  - 5.2.1.4 Other organoid type
- 5.2.2 By Method
  - 5.2.2.1 General submerged method for organoid culture
  - 5.2.2.2 Crypt organoid culture techniques
  - 5.2.2.3 Air Liquid Interface (ALI) method
  - 5.2.2.4 Other organoid methods
- 5.2.3 By Source
  - 5.2.3.1 Primary tissue
  - 5.2.3.2 Stem cells
5.3 Spheroids
- 5.3.1 By Type
  - 5.3.1.1 Multicellular tumor spheroids
  - 5.3.1.2 Neurospheres
  - 5.3.1.3 Mammospheres
  - 5.3.1.4 Hepatospheres
- 5.3.2 By Method
  - 5.3.2.1 Micropatterned plates
  - 5.3.2.2 Low cell attachment plates
  - 5.3.2.3 Hanging drop method
  - 5.3.2.4 Other spheroid methods
- 5.3.3 By Source
  - 5.3.3.1 Cell line
  - 5.3.3.2 iPSCs derived cells

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Developmental biology
6.3 Personalized medicine
6.4 Regenerative medicine
6.5 Disease pathology studies
6.6 Drug toxicity & efficacy testing

Chapter 7 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Pharmaceutical & biotechnology companies
7.3 Academic & research institutes
7.4 Hospital & diagnostic centers

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa